CSF2 and pulmonary alveolar proteinosis: The results of a meta-analysis of the therapeutic efficacy of GM-CSF for PAP showed that 76.5% and 43% of PAP patients using inhaled and subcutaneous GM-CSF, respectively, responded to treatment [17].